CUE Cue Biopharma
- 1.740
- -0.170-8.90%
- 1.740
- 0.0000.00%
Cue Biopharma News
Cue Biopharma's Promising Future: A Comprehensive Buy Rating Justification
Cue Biopharma First Quarter 2024 Earnings: Beats Expectations
Cue Biopharma Shares Are Trading Lower. The Company Reported Q1 Financial Results.
Cue Biopharma Shares Are Trading Lower. The Company Reported Q1 Financial Results.
Oppenheimer Reaffirms Their Buy Rating on Cue Biopharma (CUE)
Cue Biopharma (CUE.US): The 2024 Q1 financial report achieved revenue of US$1,717,000, with a previous value of US$187,000 and an expected value of US$1.21 million; earnings per share were -0.25 dollars, the previous value was -0.29 dollars, and the expec
Cue Biopharma (CUE.US): The 2024 Q1 financial report achieved revenue of US$1,717,000, with a previous value of US$187,000 and an expected value of US$1.21 million; earnings per share were -0.25 dollars, the previous value was -0.29 dollars, and the expected value was -0.28 dollars.
Cue Biopharma Q1 2024 Adj EPS $(0.25) Beats $(0.28) Estimate
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) by 10.71 percent.
Cue Biopharma | 10-Q: Quarterly report
Cue Biopharma 1Q Loss $12.3M >CUE
Cue Biopharma 1Q Loss $12.3M >CUE
Cue Biopharma to Present at the 20th Annual PEGS Boston Summit
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disea
Cue Biopharma to Participate in Fireside Chat at The Citizens JMP Life Sciences Conference
BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disea
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now
Cue Biopharma (CUE.US): The 2023 Q4 earnings report achieved revenue of $1,821,000, with an estimated value of $1.71 million; earnings per share were -0.28 US dollars, the previous value was -0.37 US dollars, and the expected value was -0.28 US dollars.
Cue Biopharma (CUE.US): The 2023 Q4 earnings report achieved revenue of $1,821,000, with an estimated value of $1.71 million; earnings per share were -0.28 US dollars, the previous value was -0.37 US dollars, and the expected value was -0.28 US dollars.
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
Throughout the last three months, 4 analysts have evaluated Cue Biopharma (NASDAQ:CUE), offering a diverse set of opinions from bullish to bearish.The following table summarizes their recent ratings,
Cue Biopharma: A Strong Buy on Clinical Breakthroughs and Strategic Financial Positioning
Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel
Cue Biopharma Price Target Maintained With a $8.00/Share by Stifel
Oppenheimer: Maintaining the Cue Biopharma (CUE.US) rating, adjusted from superior to superior market ratings, and adjusted the target price from $10.00 to $10.00.
Oppenheimer: Maintaining the Cue Biopharma (CUE.US) rating, adjusted from superior to superior market ratings, and adjusted the target price from $10.00 to $10.00.
Oppenheimer Maintains Outperform on Cue Biopharma, Maintains $10 Price Target
Oppenheimer analyst Leland Gershell maintains Cue Biopharma (NASDAQ:CUE) with a Outperform and maintains $10 price target.
Oppenheimer Remains a Buy on Cue Biopharma (CUE)
Cue Biopharma (CUE) Gets a Buy From Stifel Nicolaus
Analysis
Price Target
No Data
